BIOMAT Database Logo BIOMAT Database Logo

Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. 1993

A I Lazarovits, and J Rochon, and L Banks, and D J Hollomby, and N Muirhead, and A M Jevnikar, and M J White, and P L Amlot, and L Beauregard-Zollinger, and C R Stiller
Multi-Organ Transplant Service, University Hospital, London, Ontario, Canada.

mAb directed against CD7 have been shown to inhibit T cell proliferation in the allogeneic mixed lymphocyte reaction suggesting that CD7 may be an appropriate target for in vivo immunotherapy. We performed a prospective randomized clinical trial with a human-mouse chimeric CD7 mAb (SDZCHH380) and compared it with murine OKT3 for the prophylaxis of kidney transplant rejection. Twenty recipients of first cadaveric renal allografts were randomized to receive either SDZCHH380 or OKT3. SDZCHH380 was well tolerated. Rejection was delayed to day 35. No patients were sensitized to SDZCHH380. In contrast 7/10 OKT3 patients made anti-OKT3 antibodies. SDZCHH380 coated peripheral blood and lymph node T cells and, in contrast to OKT3, induced minimal release of IL-2, IL-6, TNF-alpha, and IFN-gamma. In addition, we showed that CD7-negative T cells mediated rejection in one of the SDZCHH380-treated patients. We conclude that the human-mouse chimeric CD7 mAb SDZCHH380 is well tolerated, is not immunogenic, and merits further study in the prophylaxis of transplant rejection.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

A I Lazarovits, and J Rochon, and L Banks, and D J Hollomby, and N Muirhead, and A M Jevnikar, and M J White, and P L Amlot, and L Beauregard-Zollinger, and C R Stiller
Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection: analysis beyond 4 years.
January 1997, Transplantation proceedings,
A I Lazarovits, and J Rochon, and L Banks, and D J Hollomby, and N Muirhead, and A M Jevnikar, and M J White, and P L Amlot, and L Beauregard-Zollinger, and C R Stiller
The effect of anti-TfR mouse/human chimeric antibody on anti-transplant rejection.
February 2011, Transplant international : official journal of the European Society for Organ Transplantation,
A I Lazarovits, and J Rochon, and L Banks, and D J Hollomby, and N Muirhead, and A M Jevnikar, and M J White, and P L Amlot, and L Beauregard-Zollinger, and C R Stiller
Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis.
September 1992, The Journal of rheumatology,
A I Lazarovits, and J Rochon, and L Banks, and D J Hollomby, and N Muirhead, and A M Jevnikar, and M J White, and P L Amlot, and L Beauregard-Zollinger, and C R Stiller
Anti-LFA-1 adhesion molecule monoclonal antibody in prophylaxis of human kidney allograft rejection.
February 1995, Transplantation proceedings,
A I Lazarovits, and J Rochon, and L Banks, and D J Hollomby, and N Muirhead, and A M Jevnikar, and M J White, and P L Amlot, and L Beauregard-Zollinger, and C R Stiller
CD4 and CD25 monoclonal antibody cocktail in kidney transplant rejection prophylaxis: clinical results of a pilot study.
April 1995, Transplantation proceedings,
A I Lazarovits, and J Rochon, and L Banks, and D J Hollomby, and N Muirhead, and A M Jevnikar, and M J White, and P L Amlot, and L Beauregard-Zollinger, and C R Stiller
Monoclonal antibody radioimmunodetection of transplant rejection.
October 1985, Transplantation,
A I Lazarovits, and J Rochon, and L Banks, and D J Hollomby, and N Muirhead, and A M Jevnikar, and M J White, and P L Amlot, and L Beauregard-Zollinger, and C R Stiller
Recombinant human-mouse chimeric monoclonal antibody specific for human adenocarcinoma associated antigen.
February 1991, Hybridoma,
A I Lazarovits, and J Rochon, and L Banks, and D J Hollomby, and N Muirhead, and A M Jevnikar, and M J White, and P L Amlot, and L Beauregard-Zollinger, and C R Stiller
[Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
March 2002, Nihon rinsho. Japanese journal of clinical medicine,
A I Lazarovits, and J Rochon, and L Banks, and D J Hollomby, and N Muirhead, and A M Jevnikar, and M J White, and P L Amlot, and L Beauregard-Zollinger, and C R Stiller
A simple methodology for conversion of mouse monoclonal antibody to human-mouse chimeric form.
January 2013, Clinical & developmental immunology,
A I Lazarovits, and J Rochon, and L Banks, and D J Hollomby, and N Muirhead, and A M Jevnikar, and M J White, and P L Amlot, and L Beauregard-Zollinger, and C R Stiller
Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions.
December 1989, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!